

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

01 Jun 2026

### Effect of pentoxifylin on reducing erythropoietin needs in peritoneal dialysis patients with anemia

#### Protocol summary

moinzade@resident.mui.ac.ir

#### Summary

The purpose of this study was evaluation of effect of pentoxifylin on hemoglobin level and erythropoietin dose changing in hemodialysis patients with anemia. This study was done in hemodialysis centers in Isfahan (Zahraye Marziye) and Khomeini Shahr (Saei). Patients who were on hemodialysis for at least one month and without infection or bleeding in the last month were assigned in one of the following groups after full satisfaction of participation in research. The patients received pentoxifylin tablet, 400mg or placebo. Blood levels of Hemoglobin, Iron, Ferritin, serum iron binding capacity, and need to erythropoietin were measured and compared between groups.

#### Recruitment status

**Recruitment complete**

#### Funding source

Vice Chancellor for Research, Isfahan University of Medical Sciences

#### Expected recruitment start date

2009-04-04, 1388/01/15

#### Expected recruitment end date

2010-09-06, 1389/06/15

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### General information

#### Acronym

#### IRCT registration information

IRCT registration number: **IRCT201101012417N6**

Registration date: **2011-01-13, 1389/10/23**

Registration timing: **retrospective**

Last update:

Update count: **0**

#### Registration date

2011-01-13, 1389/10/23

#### Registrant information

#### Name

Firouzeh Moeinzadeh

#### Name of organization / entity

Isfahan University of Medical Sciences

#### Country

Iran (Islamic Republic of)

#### Phone

+98 31 1625 5555

#### Email address

#### Scientific title

Effect of pentoxifylin on reducing erythropoietin needs in peritoneal dialysis patients with anemia

#### Public title

Effect of pentoxifylin on reducing erythropoietin needs in peritoneal dialysis patients with anemia

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

Inclusion criteria: patient's satisfaction, hemodialysis for at least 1 month prior to the study, hemoglobin concentration less than 10g/dL in at least 2 episodes, Erythropoietin use more than 12000 units per week, no bleeding over the last month prior to the intervention, no infection resulting admission over the last month prior to the intervention, vitamin C consumption 250mg twice a week Exclusion criteria: drug intolerance, bleeding during the study period, infection resulting admission

#### Age

From **18 years** old to **90 years** old

#### Gender

Both

**Phase**

N/A

**Groups that have been masked***No information***Sample size**

Target sample size: 50

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Vice Chancellor for Research, Isfahan University of Medical Sciences

**Street address**

Isfahan 1000 jarib

**City**

Isfahan

**Postal code****Approval date**

2010-02-20, 1388/12/01

**Ethics committee reference number**

287028

**Health conditions studied****1****Description of health condition studied**

End Stage Renal Disease

**ICD-10 code**

N18.0

**ICD-10 code description**

End-stage renal disease

**Primary outcomes****1****Description**

serum hemoglobin level

**Timepoint**

Baseline, monthly, at the end of the study

**Method of measurement**

g/dL

**2****Description**

serum albumin

**Timepoint**

Baseline, monthly, at the end of the study

**Method of measurement**

g/dL

**3****Description**

Erythropoietin use

**Timepoint**

monthly

**Method of measurement**

International unit

**Secondary outcomes****1****Description**

serum Iron level

**Timepoint**

Baseline, 3rd month, at the end of study

**Method of measurement**

µg/dL

**2****Description**

Total iron binding capacity

**Timepoint**

Baseline, 3rd month, at the end of study

**Method of measurement**

µg/dL

**Intervention groups****1****Description**

Pentoxifylin, 400mg orally daily for 6 months

**Category**

Treatment - Drugs

**2****Description**

Placebo daily for 6 months orally

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Peritoneal dialysis center. Alzahra hospital

**Full name of responsible person**

Mrs. Karimi  
**Street address**  
Alzahra hospital, Sofe Ave, Isfahan  
**City**  
Isfahan

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**  
Vice Chancellor for Research, Isfahan University of  
Medical Sciences  
**Full name of responsible person**  
Vice Chancellor for Research  
**Street address**  
Hezarjarib, Isfahan  
**City**  
Isfahan

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Vice Chancellor for Research, Isfahan University of  
Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

*empty*

#### Domestic or foreign origin

*empty*

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

*empty*

## Person responsible for general inquiries

#### Contact

**Name of organization / entity**  
Isfahan University of Medical Science  
**Full name of responsible person**  
Dr. Mojgan Mortazavi  
**Position**  
Associate Professor of Nephrology  
**Other areas of specialty/work**  
**Street address**  
Isfahan University of Medical Sciences  
**City**  
Isfahan  
**Postal code**  
**Phone**  
+98 31 1668 5555  
**Fax**  
**Email**  
m\_mortazavi@med.mui.ac.ir  
**Web page address**

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**  
Isfahan University of Medical Sciences  
**Full name of responsible person**  
Dr. Mojgan Mortazavi  
**Position**  
Associate Professor of Nephrology  
**Other areas of specialty/work**  
**Street address**  
Isfahan University of Medical Sciences  
**City**  
Isfahan  
**Postal code**  
**Phone**  
+98 31 1668 5555  
**Fax**  
**Email**  
m\_mortazavi@med.mui.ac.ir  
**Web page address**

## Person responsible for updating data

#### Contact

**Name of organization / entity**  
Isfahan University of Medical Sciences  
**Full name of responsible person**  
Dr Firouzeh Moeinzadeh  
**Position**  
Assistant Professor of Internal Medicine  
**Other areas of specialty/work**  
**Street address**  
Azahra Hospital, Isfahan  
**City**  
Isfahan  
**Postal code**  
**Phone**  
+98 31 1668 5555  
**Fax**  
**Email**  
moinzade@resident.mui.ac.ir  
**Web page address**

## Sharing plan

#### Deidentified Individual Participant Data Set (IPD)

*empty*

#### Study Protocol

*empty*

#### Statistical Analysis Plan

*empty*

#### Informed Consent Form

*empty*

#### Clinical Study Report

*empty*

#### Analytic Code

*empty*

#### Data Dictionary

*empty*